Joke Bilcke - Infectious Diseases

Author Information

Joke Bilcke is a distinguished researcher affiliated with the Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID) at the Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, located in Wilrijk, Belgium. Her work primarily revolves around the economic analysis and modeling of infectious diseases, contributing significantly to the understanding and development of effective health strategies and interventions.

Research Contributions

Joke Bilcke has made substantial contributions to the field of infectious diseases through her research, which often focuses on the cost-effectiveness and impact of vaccination strategies. Notably, her work includes studies on the economic impact of adding oseltamivir to the standard care for influenza-like illness, evaluating vaccination strategies for antimicrobial-resistant typhoid fever, and assessing preventive strategies for respiratory syncytial virus in children. Her research is characterized by the use of mathematical modeling to inform public health decisions and improve health outcomes.

Aliases

Joke Bilcke is also known by various aliases including J Bilcke and J. Bilcke. These variations are used interchangeably in academic publications and databases.

Publication and Citation Metrics

Citation Count	2311
h-index	27
Paper Count	82

Publications:

Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness.

DOI: 10.1016/j.jval.2021.08.001

Year: 2022

Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study.

DOI: 10.1016/s1473-3099(21)00627-7

Year: 2022

Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.

DOI: 10.1093/infdis/jiac064

Year: 2022

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine

DOI: 10.1007/s40273-021-01099-2

Year: 2022

Belgian population norms for the EQ-5D-5L, 2018

DOI: 10.1007/s11136-021-02971-6

Year: 2021

Strategies for typhoid conjugate vaccines in endemic nations - Authors' reply.

DOI: 10.1016/S1473-3099(21)00018-9

Year: 2021

Estimating the Impact of Vaccination on Antimicrobial-Resistant Typhoid Fever in Gavi-73 Countries

DOI: 10.2139/ssrn.3844858

Year: 2021

Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial

DOI: 10.1007/s40261-021-01057-y

Year: 2021

Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice

DOI: 10.1177/0272989X211045070

Year: 2021

Belgian population norms for the EQ-5D-5L, 2013 and 2018

DOI: 10.1093/eurpub/ckaa165.332

Year: 2020

What are Direct Acting Antivirals (DAAs)?

What Role Do Vaccines Play in Preventing Airborne Diseases?

What is the Treatment for Salmonella?

How is the Immune System Studied?

What Does the Future Hold for Personalized Medicine in Infectious Diseases?

Are Vaccines Safe?

How Can Hygiene Practices be Implemented in Healthcare Settings?

What is Dexamethasone?

Are There Vaccines Available for Diseases Transmitted by Aedes Aegypti?

What is E. Coli?

Partnered Content Networks

Relevant Topics